Durable response of multiple myeloma and non‐small cell lung cancer with simultaneous, biologically targeted treatment

Kaiser, Martin; Croft, James; Shah, Paras; Yousaf, Nadia; Popat, Sanjay

doi:10.1111/bjh.16393

Cited by 6 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…M.F. Kaiser et al описали пациента с нерезектабельным раком легкого (T3 N0 M1b) и множественной миеломой, на примере которого был продемонстрирован положительный клинический эффект от терапии пембролизумабом и даратумумабом в сочетании с карфилзомибом и дексаметазоном [17]. Пембролизумаб -моноклональное антитело, ингибитор PD-1, повышенная экспрессия которого наблюдается при немелкоклеточном раке легкого.…”

Section: Discussionunclassified

The importance of oncological alertness in the differential diagnosis of inflammatory changes in the lungsdetected as a result of differential diagnosis of pneumonia

Petrukhnova,

Voronkova,

Buyanova

et al. 2024

Medicinskij sovet

View full text Add to dashboard Cite

This article describes a case of lung cancer, the symptoms of which have long been regarded as manifestations of pneumonia; the stages of diagnostic search from the first symptoms of cancer to radical treatment are revealed. At the same time, the patient was diagnosed with monoclonal gammopathy of unknown significance, which at the stage of differential diagnosis suggested the development of synchronous cancer – lung cancer and the onset of multiple myeloma (MM). A number of literature sources were analyzed, according to the results of the analysis, it was found that at the moment six cases of the development of synchronous lung cancer and ММ have been described in the world, in most of which the age of patients was less than 70 years, which indicates a relatively early development of ММ. The issues of differential diagnosis of pneumonia and lung cancer are considered; the importance of early detection of malignant neoplasms (especially at the outpatient stage) is emphasized. It has been established that in some cases pneumonia can mask cancer, especially the detection of neoplasia after diagnosing pneumonia of the upper lobe localization. It has been suggested that the pathogenesis of lung cancer and ММ associated with intensive expression of CD38 may be common, and an example of a positive clinical effect on unresectable lung cancer with daratumumab is given (CD38-blocking monoclonal antibody used in MM therapy). At the same time, the revealed observation of the combined development of oncological diseases is very interesting, since in patients with different types of cancer, as a rule, each tumor tends to develop sequentially. However, our case was analyzed in comparison with literature data with cases of concomitant development of multiple myeloma and lung cancer simultaneously. At the same time, common genes and related pathogenesis of progression of two types of tumors were identified due to activation of the expression of the mitochondrial trans-2-enoyl-CoA reductase (MECR) concentrator gene.

show abstract

Section: Discussionunclassified

The importance of oncological alertness in the differential diagnosis of inflammatory changes in the lungsdetected as a result of differential diagnosis of pneumonia

Petrukhnova,

Voronkova,

Buyanova

et al. 2024

Medicinskij sovet

View full text Add to dashboard Cite

show abstract

“…When suffering from lung cancer and MM, the chronological occurrence of the two cancers needs to be clarified. Fewer than 20 cases of MM with lung cancer have been reported so far; four of these cases were lung adenocarcinoma cases and MM and lung cancer occurred simultaneously in only two cases (11,(13)(14)(15)(16)(17)(18)(19)(20). Zuo et al (17) reported a rare case of simultaneous MM and pulmonary adenocarcinoma; the patient was treated with bortezomib and is stable.…”

Section: Discussionmentioning

confidence: 99%

Simultaneous multiple myeloma and non‑small cell lung carcinoma: A case report and review of the literature

Dong

Kang

et al. 2022

Oncol Lett

View full text Add to dashboard Cite

Multiple myeloma (MM) is the second commonest hematologic malignancy. Synchronous presentation of MM and lung cancer is a rare occurrence. The present study reports a case of MM combined with lung cancer and reviews previously reported cases of the co-existence of non-small cell lung carcinoma and MM. At Hebei General Hospital (Shijiazhuang, China), a 52-year-man was diagnosed with MM complicated by lung lesion. Lung computed tomography (CT) showed an increase in lesion density after the second cycle of chemotherapy. The lesion was surgically removed and the patient was diagnosed with non-small cell lung carcinoma by lung biopsy pathology. After the fifth cycle of VDT (bortezomib, dexamethasone and thalidomide), the patient received autologous stem cell transplantation. Immunohistochemical staining for CD38, CD138, CD39, CD203a and TNF-α were positive in both MM and lung cancer; CD73 was only positive in lung cancer. The present study described the rare event of the simultaneous occurrence of MM and lung adenocarcinoma and discussed the potential link between the two tumors. CD38 may play a role in MM and lung cancer by changing the bone marrow microenvironment through adenosine.

show abstract

“…Kaiser et al. ( 4 ) described their experience treating a 68-year-old man who was diagnosed with non-small cell lung cancer by image-guided biopsy 10 years after being treated for MM. Marinopoulos et al.…”

Section: Discussionmentioning

confidence: 99%

Simultaneous Presentation of Multiple Myeloma and Lung Cancer: Case Report and Gene Bioinformatics Analysis

Xiao¹,

Luo²,

Wang³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Patients diagnosed with more than one cancer generally develop the individual tumors sequentially. There are a few cases of co-occurring multiple myeloma and lung cancer reported in the literature. Here, we report two cases of co-occurring multiple myeloma and lung cancer in patients who presented with the chief complaint of pain. The diagnoses of multiple myeloma and lung cancer were supported by hematologic and biochemical investigations, as well as bone marrow and lung histopathologic examination. We provided suitable interventions for both two patients. The patients are still currently undergoing treatment and followed up closely. We first performed a bioinformatic analysis to determine commonly shared genes and pathways in the two types of cancer types. Fortunately, we identified the hub gene mitochondrial trans-2-enoyl-CoA reductase (MECR), which was overexpressed in both tumors. Survival analysis correlated higher MECR expression with poorer overall survival. Signaling pathway analysis suggested possible transduction pathways implicated in the co-occurrence of both tumors. The clinical cases combined with bioinformatic analysis may provide insight for the pathogenesis of synchronous tumors.

show abstract

Durable response of multiple myeloma and non‐small cell lung cancer with simultaneous, biologically targeted treatment

Cited by 6 publications

References 8 publications

The importance of oncological alertness in the differential diagnosis of inflammatory changes in the lungsdetected as a result of differential diagnosis of pneumonia

The importance of oncological alertness in the differential diagnosis of inflammatory changes in the lungsdetected as a result of differential diagnosis of pneumonia

Simultaneous multiple myeloma and non‑small cell lung carcinoma: A case report and review of the literature

Simultaneous Presentation of Multiple Myeloma and Lung Cancer: Case Report and Gene Bioinformatics Analysis

Contact Info

Product

Resources

About